⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177132 | 1.00 | — | — | |
| SCHEMBL19682198 | 0.82 | — | — | |
| SCHEMBL16501774 | 0.76 | L3MBTL1 (0.30) | — | |
| SCHEMBL13967018 | 0.76 | L3MBTL1 (0.30) | — | |
| SCHEMBL19730344 | 0.74 | — | — | |
| SCHEMBL19682054 | 0.68 | ALDH1A1 (0.33) | — | |
| SCHEMBL17662565 | 0.67 | MMP8 (0.32) | — | |
| SCHEMBL13166782 | 0.66 | L3MBTL1 (0.32) | — | |
| SCHEMBL14010448 | 0.64 | SLC6A3 (0.42) | — | |
| SCHEMBL18653492 | 0.64 | SLC6A3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190167806-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEATTLE GENETICS, INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20160310612-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEATTLE GENETICS, INC. (US) | 2016-10-27 | — | — | US | disclosed |